CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders

Translational Psychiatry

Volumn 3, Issue , 2013, Pages

  Mattsson, N ^a,b,c   Insel, P ^a   Nosheny, R ^a   Zetterberg, H ^b,d   Trojanowski, J Q ^e   Shaw, L M ^e   Tosun, D ^a,c   Weiner, M ^a,c  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer's disease; Beta amyloid; Biomarker; Cerebrospinal fluid; Longitudinal; Microglia

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BETA 2 MICROGLOBULIN; CD40 ANTIGEN; CHROMOGRANIN A; CLUSTERIN; COLONY STIMULATING FACTOR 1; CXCL9 CHEMOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOGEN; FOLLITROPIN; IMMUNOGLOBULIN A; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN TYROSINE KINASE; SERUM AMYLOID P; SOMATOMEDIN BINDING PROTEIN 2; TAU PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VON WILLEBRAND FACTOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); AXL RECEPTOR TYROSINE KINASE; BIOLOGICAL MARKER; ONCOPROTEIN; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MALE; MICROGLIA; MINI MENTAL STATE EXAMINATION; NORMAL HUMAN; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN METABOLISM; SYNAPSE; SYNAPTIC POTENTIAL; CEREBROSPINAL FLUID; METABOLISM; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; CHROMOGRANIN A; FEMALE; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MICROGLIA; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PLAQUE, AMYLOID; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; ROC CURVE; SYNAPSES;

EID: 84883116877     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2013.69     Document Type: Article

References (35)

1. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003; 60: 652-656. (Pubitemid 36246085)
2. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003; 60: 1696-1702. (Pubitemid 37521622)
3. Engelborghs S, De Vreese K, Van De Casteele T, Vanderstichele H, Van Everbroeck B, Cras P et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 2008; 29: 1143-1159. (Pubitemid 351822410)
4. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-413.
5. Choi SR, Schneider JA, Bennett DA, Beach TG, Bedell BJ, Zehntner SP et al. Correlation of amyloid PET ligand florbetapir F 18 binding with Abeta aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord 2012; 26: 8-16.
6. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 2012; 11: 669-678.
7. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59: 512-519. (Pubitemid 43358072)
8. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367: 795-804.
9. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131-144.
10. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5-10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69: 98-106.
11. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011; 69: 181-192.
12. Peskind ER, Li G, Shofer J, Quinn JF, Kaye JA, Clark CM et al. Age and apolipoprotein E4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol 2006; 63: 936-939. (Pubitemid 44036292)
13. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013; 368: 117-127.
14. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013; 368: 107-116.
15. Koffie RM, Hyman BT, Spires-Jones TL. Alzheimer's disease: synapses gone cold. Mol Neurodegener 2011; 6: 63.
16. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005; 48: 913-922. (Pubitemid 41814696)
17. Mattsson N, Tabatabaei S, Johansson P, Hansson O, Andreasson U, Mansson JE et al. Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med 2011; 13: 151-159.
18. Willis M, Leitner I, Jellinger KA, Marksteiner J. Chromogranin peptides in brain diseases. J Neural Transm 2011; 118: 727-735.
19. Jack Jr. CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-128.
20. Llano DA, Laforet G, Devanarayan V; Alzheimer's Disease Neuroimaging Initiative. Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord 2011; 25: 73-84.
21. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM et al. Relationships between biomarkers in aging and dementia. Neurology 2009; 73: 1193-1199.
22. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM et al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol 2010; 119: 669-678.
23. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One 2011; 6: e18850.
24. Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 2012; 79: 897-905.
25. Pinheiro J, Bates D, DebRoy S, Sarkar D and the R Development Core Team. nlme: linear and nonlinear mixed effects models. R package version 3.1-110, 2013.
26. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics 2005; 21: 3940-3941. (Pubitemid 41535515)
27. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S et al. The Alzheimer's association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 2011; 7: 386-395, e386.
28. Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS et al. Longitudinal change of biomarkers in cognitive decline. Arch Neurol 2011; 68: 1257-1266.
29. Ringman JM, Taylor K, Teng E, Coppola G, Gylys K. Longitudinal change in CSF biomarkers in a presymptomatic carrier of an APP mutation. Neurology 2011; 76: 2124-2125.
30. Kester MI, Scheffer PG, Koel-Simmelink MJ, Twaalfhoven H, Verwey NA, Veerhuis R et al. Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. Neurobiol Aging 2012; 33: 1591-1598.
31. De Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006; 27: 394-401. (Pubitemid 43185324)
32. Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N et al. Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS One 2009; 4: e6294.
33. Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol 2010; 67: 217-223.
34. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerstrom C et al. Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis 2007; 12: 255-260. (Pubitemid 350179256)
35. Fagan AM, Perrin RJ. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med 2012; 6: 455-476.